Abstract
BACKGROUND Numerous materials have been used to accomplish soft tissue augmentation, but the ideal implant remains elusive. Dermaplant is a recently introduced soft tissue matrix derived from human cadaveric dermis and intended for use in soft tissue reconstruction. This product is U.S. Food and Drug Administration (FDA) approved, but there is a paucity of data regarding its clinical performance. OBJECTIVE To report histopathologic findings of an explanted Dermaplant specimen. METHODS A healthy 52-year-old man underwent repair of postblepharoplasty eyelid retraction and a prominent tear trough defect. At the patient's request the tear trough implant was removed in the seventh postoperative week. Gross and microscopic evaluations were performed. RESULTS Fibroblastic infiltration and new collagen production were demonstrated within the implant and at its periphery. Occasional macrophages and giant cells were also noted around the implant. CONCLUSION In this patient the Dermaplant was well tolerated and supported ingrowth of host tissues. The behavior of this material over the long-term cannot be extrapolated from this study.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
